NASDAQ: GDTC
Cytomed Therapeutics Ltd Stock Ownership - Who owns Cytomed Therapeutics?

Insider buying vs selling

Have Cytomed Therapeutics Ltd insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when GDTC insiders and whales buy or sell their stock.

GDTC Shareholders

What type of owners hold Cytomed Therapeutics Ltd stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Glorious Finance Ltd40.33%4,653,604$9.68MInsider
Shu Wang7.66%883,858$1.84MInsider
Jieming Zeng5.11%589,239$1.23MInsider
Chee Kong Choo3.56%410,515$853.87kInsider
Lucas Tien Wee Luk0.80%92,563$192.53kInsider
Citadel Advisors LLC0.15%17,250$35.88kInstitution
Ubs Group Ag0.13%14,447$30.05kInstitution
Concourse Financial Group Securities Inc0.00%0$0.00Institution

1 of 1

GDTC vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
GDTC0.27%57.45%
CALC13.56%86.44%Net BuyingNet Buying
IGC3.60%25.44%Net Buying
NNVC2.76%97.24%
PASG43.94%56.06%Net SellingNet Selling

Cytomed Therapeutics Stock Ownership FAQ

Who owns Cytomed Therapeutics?

Cytomed Therapeutics (NASDAQ: GDTC) is owned by 0.27% institutional shareholders, 57.45% Cytomed Therapeutics insiders, and 42.27% retail investors. Glorious Finance Ltd is the largest individual Cytomed Therapeutics shareholder, owning 4.65M shares representing 40.33% of the company. Glorious Finance Ltd's Cytomed Therapeutics shares are currently valued at $9.68M.

If you're new to stock investing, here's how to buy Cytomed Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.